12/10/2025
Aronora is proud to share that we presented new data on AB023 and AB062 at hashtag .
AB023 is a first-in-class, Factor XI (FXI) inhibitor designed to bind the Apple 2 (A2) domain of FXI. This differentiated mechanism of action selectively inhibits Factor XII–mediated contact activation of FXI, while preserving thrombin-mediated FXI activation that supports fully functional hemostasis.
AB062 is a first-in-class, antisense oligonucleotide designed to inhibit hepatic production of thrombopoietin – a key regulator of platelet production whose signaling pathway is aberrantly activated in myeloproliferative neoplasms like essential thrombocythemia (ET).
We’re excited to hear KOLs echo our belief in the potential for Aronora's first-in-class programs to better serve patient communities at risk for life-threatening thrombosis.
Thank you to the hashtag organizers for an engaging program and we look forward to a productive year ahead!
